Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Its own activity is sensitive to the cell's NAD+ and metabolic state
A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007
Short-term storage ( 2 weeks): 4 C (39 F)
If you're in Ponte Vedra Beach, Jacksonville, Nocatee, or anywhere in the 32081 area and want to explore BPC-157 or our broader peptide therapy program, we're here to have that conversation
This triple-agonist design was first reported by Coskun and colleagues as a next-generation expansion of Tirzepatides dual incretin framework (Coskun et al., 2022
